Background glaucoma Shape Background glaucoma Shape Background glaucoma Shape
Grants > Inhibition of Apoptosis in Experimental Glaucoma Updated On: Ene. 23, 2025
National Glaucoma Research Grant

Inhibition of Apoptosis in Experimental Glaucoma

Principal Investigator

Stuart McKinnon, MD, PhD

Duke University Eye Center

Durham, NC, USA

About the Research Project

Program

National Glaucoma Research

Award Type

Standard

Award Amount

$50,000

Active Dates

April 01, 2000 - March 31, 2002

Grant ID

G2000008

Summary

In glaucoma, the loss of retinal ganglion cells (RGC) proceeds by a mechanism known as apoptosis. Apoptosis is an organized, or programmed, form of cell death that requires the action of a series of proteases (proteins that chop up other proteins) called caspases. In animal models of glaucoma, the protease Caspase-3 is found to be activated in RGCs, where it also cleaves a molecule called amyloid precursor protein (APP). APP is important in Alzheimer’s disease (AD) as well as in glaucoma. In fact, the excessive production of smaller fragments of APP, called amyloid beta, is a hallmark of AD and is thought to be toxic to neurons. Dr. McKinnon is interested in the fact that these two different neurodegenerative diseases, glaucoma and AD, share some key features. He is examining the apoptotic death of RGCs and the possible role of APP in more detail. An understanding of RGC apoptosis could be important in devising protective strategies for preventing glaucomatous damage, and these studies may also illuminate general features of nerve cell death in the central nervous system, making them relevant to other neurodegenerative diseases like AD.